Jun Wang - Publications
Affiliations: | Pharmaceutical Sciences | State University of New York, Buffalo, Buffalo, NY, United States |
Year | Citation | Score | |||
---|---|---|---|---|---|
2023 | Wang J, Chen T, Ruszaj DM, Mager DE, Straubinger RM. Integrated PK/PD modeling relates Smoothened inhibitor biomarkers to the heterogeneous intratumor disposition of cetuximab in pancreatic cancer tumor models. Journal of Pharmaceutical Sciences. PMID 37844759 DOI: 10.1016/j.xphs.2023.10.019 | 0.574 | |||
2020 | Greene MK, Chen T, Robinson E, Straubinger NL, Minx C, Chan DKW, Wang J, Burrows JF, Van Schaeybroeck S, Baker JR, Caddick S, Longley DB, Mager DE, Straubinger RM, Chudasama V, et al. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer. PMID 32913288 DOI: 10.1038/S41416-020-01046-6 | 0.552 | |||
2019 | Wang J, Chan DK, Sen A, Ma WW, Straubinger RM. Tumor priming by SMO inhibition enhances antibody delivery and efficacy in a pancreatic ductal adenocarcinoma model. Molecular Cancer Therapeutics. PMID 31363010 DOI: 10.1158/1535-7163.Mct-18-0354 | 0.661 | |||
2018 | Chan D, Minx C, Wang J, Sen A, Johnston M, Ma WW, Scott CJ, Straubinger RM. Abstract 3704: Efficacy of DR5-targeted immunoliposomes in pancreatic cancer models primed with SMO inhibitors Cancer Research. 78: 3704-3704. DOI: 10.1158/1538-7445.Am2018-3704 | 0.604 | |||
2014 | Wang J, Qu Y, Pitoniak R, Trueman-Fatallah SA, Hylander BL, Repasky EA, Ma WW, Straubinger RM. Abstract 2691: Smo-targeted sonic hedgehog signaling inhibitor enhances therapeutic antibody deposition and efficacy in a patient-derived pancreatic ductal adenocarcinoma model Cancer Research. 74: 2691-2691. DOI: 10.1158/1538-7445.Am2014-2691 | 0.61 | |||
Show low-probability matches. |